ATE221387T1 - Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe - Google Patents
Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffeInfo
- Publication number
- ATE221387T1 ATE221387T1 AT94915447T AT94915447T ATE221387T1 AT E221387 T1 ATE221387 T1 AT E221387T1 AT 94915447 T AT94915447 T AT 94915447T AT 94915447 T AT94915447 T AT 94915447T AT E221387 T1 ATE221387 T1 AT E221387T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- lhrh
- peptide
- helper
- cell epitope
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 14
- 230000002163 immunogen Effects 0.000 title abstract 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 title 1
- 238000010276 construction Methods 0.000 title 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 10
- 108700012941 GNRH1 Proteins 0.000 abstract 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 6
- 230000001419 dependent effect Effects 0.000 abstract 3
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 3
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 101710198693 Invasin Proteins 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 102400000921 Gastrin Human genes 0.000 abstract 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 abstract 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
- 101710105759 Major outer membrane porin Proteins 0.000 abstract 1
- 101710164702 Major outer membrane protein Proteins 0.000 abstract 1
- 241000224017 Plasmodium berghei Species 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 208000025661 ovarian cyst Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002381 testicular Effects 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 201000007331 uterine benign neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57572—Gastrin releasing peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5716693A | 1993-04-27 | 1993-04-27 | |
| US22927594A | 1994-04-14 | 1994-04-14 | |
| PCT/US1994/004832 WO1994025060A1 (en) | 1993-04-27 | 1994-04-28 | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE221387T1 true ATE221387T1 (de) | 2002-08-15 |
Family
ID=26736147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94915447T ATE221387T1 (de) | 1993-04-27 | 1994-04-28 | Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0708656B1 (enExample) |
| JP (2) | JP3795914B2 (enExample) |
| AT (1) | ATE221387T1 (enExample) |
| AU (1) | AU687805B2 (enExample) |
| CA (1) | CA2161445C (enExample) |
| DE (1) | DE69431114T2 (enExample) |
| DK (1) | DK0708656T3 (enExample) |
| ES (1) | ES2180576T3 (enExample) |
| FI (1) | FI955101A7 (enExample) |
| NO (1) | NO316121B1 (enExample) |
| WO (1) | WO1994025060A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| EP1375511B1 (en) * | 1993-02-26 | 2007-04-11 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| CN1146772A (zh) * | 1994-03-28 | 1997-04-02 | 美国联合生物医学公司 | 用于治疗过敏反应的合成肽免疫原 |
| US6410022B1 (en) * | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
| ES2190470T3 (es) | 1995-06-06 | 2003-08-01 | Avant Immunotherapeutics Inc | Cetp para incrementar el nivel de colesterol de las hdl. |
| US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
| AU719609B2 (en) | 1996-03-01 | 2000-05-11 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
| DE69736226T2 (de) | 1996-04-19 | 2006-11-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren |
| CA2252438C (en) * | 1996-04-19 | 2011-03-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| US6284533B1 (en) | 1996-05-01 | 2001-09-04 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
| US6846808B1 (en) | 1996-05-01 | 2005-01-25 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
| US6309646B1 (en) | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
| ATE421331T1 (de) * | 1996-06-25 | 2009-02-15 | Pepscan Systems Bv | Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff |
| ES2255181T3 (es) * | 1997-08-05 | 2006-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antigeno inmunoprotector contra la gripe y su uso en vacunacion. |
| CA2315537A1 (en) | 1997-12-16 | 1999-06-24 | Regents Of The University Of Minnesota | Methods to treat undesirable immune responses |
| US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| US6025468A (en) * | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| US6107021A (en) * | 1998-06-20 | 2000-08-22 | United Biomedical, Inc. | Synthetic peptide vaccines for foot-and-mouth disease |
| WO2000032626A1 (en) * | 1998-11-25 | 2000-06-08 | Regents Of The University Of Minnesota | Methods of using epitope peptides of human pathogens |
| UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2001259452A1 (en) | 2000-05-05 | 2001-11-20 | Aphton Corporation | Chimeric peptide immunogens their preparation and use |
| US6780969B2 (en) * | 2000-12-22 | 2004-08-24 | United Biomedical, Inc. | Synthetic peptide composition as immunogens for prevention of urinary tract infection |
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| WO2003089460A1 (en) * | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
| CN1777439A (zh) | 2003-04-22 | 2006-05-24 | 研究及应用科学协会股份有限公司 | 生长抑素的载体 |
| ZA200702329B (en) * | 2004-09-10 | 2008-06-25 | Queensland Inst Med Res | Truncated LHRH formulations |
| US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
| MX2007015151A (es) * | 2005-06-01 | 2008-02-15 | Pfizer Prod Inc | Composiciones de vacunas y metodos para el tratamiento de la incontinencia urinaria. |
| EP2187924A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of a peptide as a therapeutic agent |
| JP4535174B2 (ja) | 2008-07-11 | 2010-09-01 | トヨタ自動車株式会社 | 車両の制御装置および制御方法 |
| US10420832B2 (en) | 2012-11-16 | 2019-09-24 | United Biomedical, Inc. | Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD) |
| EP3191119A4 (en) * | 2014-07-25 | 2018-01-24 | United Biomedical, Inc. | Immunogenic lhrh composition and use thereof in pigs |
| US11614448B2 (en) * | 2017-03-30 | 2023-03-28 | Ecs-Progastrin Sa | Compositions and methods for detecting prostate cancer |
| MX2021007446A (es) * | 2018-12-19 | 2021-09-08 | United Biomedical Inc | Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos. |
| TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4613586A (en) * | 1984-04-19 | 1986-09-23 | Board Of Trustees Of The Leland Stanford Junior University | Gastrin releasing peptide-like peptides |
| US4608251A (en) * | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| EP0301850A3 (en) * | 1987-07-31 | 1990-10-31 | Syntex (U.S.A.) Inc. | Lhrh antagonist analogs and 19-nor-progestational steroids for therapy |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| US5171835A (en) * | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| GB8913737D0 (en) * | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| GB8924438D0 (en) * | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
| IT1237764B (it) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| CH683101A5 (de) * | 1990-09-18 | 1994-01-14 | Biotech Australia Pty Ltd | T-Zellen-Epitope. |
| FI934866L (fi) * | 1991-05-13 | 1993-11-12 | Univ California | Liposomala polysackaridvacciner |
| CZ42794A3 (en) * | 1991-08-26 | 1994-11-16 | Cytel Corp | Hla-re-stringed ctl epitopes of hepatitis b virus |
-
1994
- 1994-04-28 EP EP94915447A patent/EP0708656B1/en not_active Expired - Lifetime
- 1994-04-28 JP JP52461494A patent/JP3795914B2/ja not_active Expired - Lifetime
- 1994-04-28 DK DK94915447T patent/DK0708656T3/da active
- 1994-04-28 AU AU66702/94A patent/AU687805B2/en not_active Expired
- 1994-04-28 DE DE69431114T patent/DE69431114T2/de not_active Expired - Lifetime
- 1994-04-28 ES ES94915447T patent/ES2180576T3/es not_active Expired - Lifetime
- 1994-04-28 AT AT94915447T patent/ATE221387T1/de active
- 1994-04-28 CA CA002161445A patent/CA2161445C/en not_active Expired - Lifetime
- 1994-04-28 WO PCT/US1994/004832 patent/WO1994025060A1/en not_active Ceased
-
1995
- 1995-10-26 NO NO19954279A patent/NO316121B1/no not_active IP Right Cessation
- 1995-10-26 FI FI955101A patent/FI955101A7/fi not_active Application Discontinuation
-
2004
- 2004-10-06 JP JP2004293637A patent/JP2005060406A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK0708656T3 (da) | 2002-12-02 |
| ES2180576T3 (es) | 2003-02-16 |
| NO954279L (no) | 1995-12-27 |
| EP0708656A4 (en) | 1999-06-23 |
| JP2005060406A (ja) | 2005-03-10 |
| FI955101A0 (fi) | 1995-10-26 |
| EP0708656A1 (en) | 1996-05-01 |
| JP3795914B2 (ja) | 2006-07-12 |
| WO1994025060A1 (en) | 1994-11-10 |
| DE69431114D1 (de) | 2002-09-05 |
| AU687805B2 (en) | 1998-03-05 |
| DE69431114T2 (de) | 2003-03-13 |
| JPH09503742A (ja) | 1997-04-15 |
| NO316121B1 (no) | 2003-12-15 |
| CA2161445C (en) | 2009-06-30 |
| AU6670294A (en) | 1994-11-21 |
| FI955101A7 (fi) | 1995-12-21 |
| NO954279D0 (no) | 1995-10-26 |
| EP0708656B1 (en) | 2002-07-31 |
| CA2161445A1 (en) | 1994-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE221387T1 (de) | Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe | |
| DE69511379D1 (en) | Immunogens gegen gonadotropin releasing hormone | |
| Thompson Jr | Immunization against GnRH in male species (comparative aspects) | |
| IL146482A0 (en) | Tek antagonists | |
| IL125590A0 (en) | Peptide immunogens | |
| WO2001032926A3 (en) | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same | |
| BG104562A (en) | Composition and method for prevention and treatment of amyloidogenic disease | |
| WO1991005563A1 (en) | Therapeutic decapeptides | |
| HU9401109D0 (en) | Recombitope peptides | |
| DE69736306D1 (de) | Rezeptor von dendritischen zellen. | |
| DE69128617D1 (de) | Zyklische gnrh-antagonisten | |
| AU585605B2 (en) | GnRH antagonists IX | |
| CA2738993C (en) | Pharmaceutical composition utilising combinations of variants of the gonadotropin-releasing hormone (gnrh) as immunogen | |
| Vance et al. | Endocrine and clinical effects of leuprolide in prostatic cancer | |
| WO2002022659A3 (en) | DISCRIMINATION BETWEEN GnRH-I AND GnRH-II | |
| Limonta et al. | Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33 (7), 1141-1148 | |
| EA200200602A1 (ru) | Вакцина, содержащая штаммы lactobacillus, для лечения воспаления предстательной железы и доброкачественной гиперплазии предстательной железы | |
| Ablin | Hormonal epidemiology of prostatic cancer | |
| Weiss et al. | Proceedings: recent studies with the methanol extraction residue fraction of tubercle bacilli (MER): efficacy of distal administration against solid tumors of experimental animals, and stimulation of cellular immunologic responsiveness in cancer patients | |
| Szmigielski et al. | EMF Standards for Occupational and Environmental Exposure in Eastern European Countries: Present Status and Trends for International Harmonization | |
| Dash et al. | Evaluation of male gonadal function in leprosy | |
| Couture | Melanoma: the management of local recurrence and in-transit metastasis | |
| Playfair | The cellular basis of autoimmunity | |
| DE1726895U (de) | Kurzwellen-therapieapparat. | |
| ES2167180A1 (es) | Preparacion de concentrados terapeuticos de factor viii antigenico y aplicacion correspondiente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0708656 Country of ref document: EP |